INDV — INDIVIOR PLC ORDINARY SHARES (Healthcare >> Drug Manufacturers - Specialty & Generic)
INDV FAQ
What is INDV's P/E ratio?
INDIVIOR PLC ORDINARY SHARES (INDV) currently trades at a P/E ratio of 18.02.
What is INDV's ROE?
INDIVIOR PLC ORDINARY SHARES reports a Return on Equity (ROE) of -174.31%.
What is INDV's dividend yield?
INDIVIOR PLC ORDINARY SHARES offers a dividend yield of 0.00%.
What is INDV's Deepscope Quality Score?
Deepscope rates INDV's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy INDV?
Deepscope's AI Timing Score for INDV is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does INDV belong to?
INDIVIOR PLC ORDINARY SHARES is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 38.09
Price
-0.17
(-0.44%)
Day Change
|
|
|---|
INDV มีคุณภาพโดยรวมพอใช้ ( คะแนนปัจจัยพื้นฐาน = 69) และ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ในอดีต ค่อนข้างต่ำ
อัตราการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ในปีก่อน เป็นลบ
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ยังไม่ดีนัก สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร พอใช้ , ...
| ปัจจัยทางคุณภาพ |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
582
|
| Magic Formula Rank by ROE |
582
|
| Magic Formula Rank by ROIC |
562
|
| Price | 38.09 |
| PBV / Sector |
-31.41 / 2.63
|
| Earning Per Share | 2.11 |
| PE / Sector |
18.02 / 24.12
|
| PEG or PE/Growth / Sector |
N/A / 0.13
|
| Average 1M Daily Value |
57.35 M
|
| Average 1W Daily Value |
55.93 M
|
| ปัจจัยทางเทคนิค |
|
57% |
| สุขภาพทางการเงิน |
|
41% |
| ประสิทธิภาพการทำกำไร |
|
66% |
| ผลตอบแทนต่อผู้ถือหุ้น |
|
4% |
| รายละเอียดการจดทะเบียน |
| Analyze Date | 2026-06-11 09:55:09 |
| Symbol | INDV |
| Name | INDIVIOR PLC ORDINARY SHARES |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 118.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,522.51 / 9,930.86 |
| ข่าว, ประมาณการ, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235
Phone: 804 379 1040
Website: https://www.indivior.com
Employees: 827
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google